{"name":"Ultragenyx Pharmaceutical","slug":"ultragenyx","ticker":"RARE","exchange":"NASDAQ","domain":"ultragenyx.com","description":"Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.","hq":"Novato, CA","founded":0,"employees":"1371","ceo":"Emil D. Kakkis","sector":"Rare Disease Biotech","stockPrice":25.98,"stockChange":-0.48,"stockChangePercent":-1.81,"marketCap":"$2.6B","metrics":{"revenue":673000000,"revenueGrowth":-2.2,"grossMargin":-28.1,"rdSpend":750000000,"netIncome":-575000000,"cash":413000000,"dividendYield":0,"peRatio":181.7,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-06-01","label":"Mepsevii patent cliff ($143.8M at risk)","drug":"Mepsevii","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":6,"colorKey":"immunology","drugs":[{"name":"Adjuvant IM Therapy","genericName":"Adjuvant IM Therapy","slug":"adjuvant-im-therapy","indication":"Other","status":"phase_2"},{"name":"Antipyretic","genericName":"Antipyretic","slug":"antipyretic","indication":"Other","status":"phase_3"},{"name":"GTX-102","genericName":"GTX-102","slug":"gtx-102","indication":"FUS-associated amyotrophic lateral sclerosis (ALS)","status":"phase_3"},{"name":"Mepsevii","genericName":"Mepsevii","slug":"mepsevii","indication":"Mucopolysaccharidosis, MPS-VII","status":"marketed"},{"name":"Placebo for oral corticosteroids","genericName":"Placebo for oral corticosteroids","slug":"placebo-for-oral-corticosteroids","indication":"Control arm in Phase 3 trial for oral corticosteroid-dependent condition (specific indication unknown)","status":"phase_3"},{"name":"Reactive Corticosteroid Taper Regimen","genericName":"Reactive Corticosteroid Taper Regimen","slug":"reactive-corticosteroid-taper-regimen","indication":"Other","status":"phase_1"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"UX003","genericName":"UX003","slug":"ux003","indication":"Hypercholesterolemia","status":"phase_3"}]}],"pipeline":[{"name":"UX003","genericName":"UX003","slug":"ux003","phase":"phase_3","mechanism":"UX003 is a recombinant human monoclonal antibody that targets angiopoietin-like 3 (ANGPTL3) protein.","indications":["Hypercholesterolemia"],"catalyst":""},{"name":"Adjuvant IM Therapy","genericName":"Adjuvant IM Therapy","slug":"adjuvant-im-therapy","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Antipyretic","genericName":"Antipyretic","slug":"antipyretic","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"GTX-102","genericName":"GTX-102","slug":"gtx-102","phase":"phase_3","mechanism":"GTX-102 is an antisense oligonucleotide that reduces production of FUS protein by targeting FUS mRNA in patients with FUS-associated neurological disease.","indications":["FUS-associated amyotrophic lateral sclerosis (ALS)","FUS-associated frontotemporal dementia (FTD)"],"catalyst":""},{"name":"Mepsevii","genericName":"Mepsevii","slug":"mepsevii","phase":"marketed","mechanism":"Small molecule","indications":["Mucopolysaccharidosis, MPS-VII"],"catalyst":""},{"name":"Placebo for oral corticosteroids","genericName":"Placebo for oral corticosteroids","slug":"placebo-for-oral-corticosteroids","phase":"phase_3","mechanism":"A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect.","indications":["Control arm in Phase 3 trial for oral corticosteroid-dependent condition (specific indication unknown)"],"catalyst":""},{"name":"Reactive Corticosteroid Taper Regimen","genericName":"Reactive Corticosteroid Taper Regimen","slug":"reactive-corticosteroid-taper-regimen","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Ultragenyx Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Ultragenyx reported fourth quarter and full year 2023 financial results, with revenue of $143.8 million and a net loss of $134.8 million.","drugName":"","sentiment":"neutral"},{"date":"2023-12-15","type":"deal","headline":"Ultragenyx Announces Collaboration with Pfizer to Develop Gene Therapy for Rare Disease","summary":"Ultragenyx announced a collaboration with Pfizer to develop a gene therapy for a rare disease.","drugName":"","sentiment":"positive"},{"date":"2023-10-27","type":"regulatory","headline":"FDA Approves Ultragenyx's Mepsevii for Treatment of Mucopolysaccharidosis Type VII","summary":"The FDA approved Mepsevii for the treatment of mucopolysaccharidosis type VII.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxPR1FuQWN1bEJnZ2RnUkVuNnJ6MVBNRWR6OEpTWU4tbmp5VUc2NnJSVUZyZzRRRDVHM1VnLWpFdjRBUDdRaGppUUh2OVd5bGtGZGIzRlY2dktMR1VOWUgwQ3NuUzgwcGNxa2hPOFk2NEQzYXpiUHRBaUJwNzhVMXU4S0lsMXBncUg4NDlEZEtGYzJNQUlvRlJQRVdJel9icTQzcGF5eGQ2T2ZlWWxTYThhczJoemRwUzhZZEtlMkVn?oc=5","date":"2026-04-06","type":"regulatory","source":"TradingView","summary":"RARE Rises as FDA Accepts Resubmitted BLA for Sanfilippo Syndrome - TradingView","headline":"RARE Rises as FDA Accepts Resubmitted BLA for Sanfilippo Syndrome","sentiment":"neutral"},{"date":"2026-04-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxPNjZ6Y0ZkdHFTR0hCdlJDSGN6WkI1bktNV1puV3lFX1F6RzZjY2o4MDBwb09VMU5tUkRBTmJBRzliZnBtOC1vbUY4NlRYYzg0NnFhQnhkMTF4VU5fUG1Hd1c4MHBtbGJfQUJhYUhFc25mbEtDOWFKMDlHaU1ZWGtPbGdiWmhza09ZOHY5bFVyVTFEZHV1ckhUWEdVeU5leVdUaGFJWmY3Qk1JYnBtMGVCRTR5amkzdGRlcnlr?oc=5","date":"2026-03-31","type":"regulatory","source":"TradingView","summary":"Ultragenyx Pharmaceutical Announces FDA Acceptance of UX016 IND - TradingView","headline":"Ultragenyx Pharmaceutical Announces FDA Acceptance of UX016 IND","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4gFBVV95cUxOWnJLV3VZZjZabjdHcFZQTXNNQjVYQnlNZGdfR1U3MnhHbWx1VW4zeUt1Ym1rNXl2NFAyVXRHbXZuZ2RENGtEZDBSUHNUcWxqXzc5N1UzcHRLNUlndE0xeFhiVElTbFpxVjV3UkgyTEdrcENiaFd6Y2VsZ05ZcVgwNmhBeFM1dC1LTzFrclhObkRyX2ZodEJIOWRZWU55TEJzandyMmx4ekZFX3NLYjcxblplbTRBYXotZlk3Y0FVVGxyeWJBMWNxNFhvVng0bElsVnQxMWhpTU92eDZPU2JMNEhR?oc=5","date":"2026-03-31","type":"regulatory","source":"The Globe and Mail","summary":"Ultragenyx Pharmaceutical Announces FDA Acceptance of UX016 IND - The Globe and Mail","headline":"Ultragenyx Pharmaceutical Announces FDA Acceptance of UX016 IND","sentiment":"neutral"},{"date":"2026-03-30","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgJBVV95cUxNd0tJX1JoVVZVdDltcDdqSlp0aExUV004U2FWeXNjeHcwMXVhbG9Uc0ZYOTRkVnpLcmdOWGNtcXNibWdrZFl2ZWZxeEZURDY0ZlJFZmtsdnZoN09oZjhGRUlBSUhOVFJrSlktMnRtbnNfYU5yNFhKVXVuRmVKNWt4cUIwNEpkM1FOZmZXQ1JlWV9WQnFyeGI5dW1jS3p3YkVRYUJGVThKUERRTU1FLUNuRi1pcERublNKemZHdEF3UjNXbG9XWXlZLWY1aGR3RnE3TlBLS29KNzd5NERHZnF3UFIxRG9CZy0ySmprVmNmdnhGLXJFOGdwakp6c0hucHR3ZFFWb1JyQ1BlODdJMHV5eE5qSU8tYng4bVp5VEdSX0Y3Z09IanJlZTQxcTlwZw?oc=5","date":"2026-03-26","type":"pipeline","source":"The Globe and Mail","summary":"Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), Alnylam Pharma (ALNY) and Ultragenyx Pharmaceutical (RARE) - The Globe and Mail","headline":"Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), Alnylam Pharma (ALNY) and Ultragenyx Pharmaceu","sentiment":"neutral"},{"date":"2026-03-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxOWjlQVmNBbVBsTlNiYzQ5R1dvanUyZjB3ZDZGUjIxWDBnWXBpWGRUbHItakl5eGFUWkpRTW5CVmJGRTZEa0ViSTZJVW5DMlB2VjFGYWxwcG9ZbEEyTjlKOWlTbXQzTHdOLXB0WFBLMFVXN0p6QllFdjhvVVlBdHhKRW9RSW5YbFU5djM3UjF0VTh4dEc4U2k3cmhKYWNmdnVyby1XclF4TGVEaV9Sci1HX2UwN3ljQkE0OWpuLWJwYlUwWVNYTGFz?oc=5","date":"2026-01-04","type":"pipeline","source":"Genetic Engineering and Biotechnology News","summary":"StockWatch: Ultragenyx, Mereo Plummet on Brittle Bone Candidate Failures - Genetic Engineering and Biotechnology News","headline":"StockWatch: Ultragenyx, Mereo Plummet on Brittle Bone Candidate Failures","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxPdWFPaGVqN1lOUGdMUVdiTklCNmo5LUZ6T19pVkpnNXJfbHdlTWp5QzR2U0xEZlpubmlsNnpiaVVMWTFSR0psSzNONjJyY3ZlM0FYRkQ4Z3ZFMWhGZnVvVXQ3LU1fckw2cHQtYkxOZGk0V19vWFMwM1NsUGtqTEF0M1BKcmV4clU4dER3dXdySFJQQVowNWI3ZQ?oc=5","date":"2025-12-29","type":"pipeline","source":"Yahoo Finance","summary":"Why Ultragenyx Pharmaceuticals Stock Is Plummeting Today - Yahoo Finance","headline":"Why Ultragenyx Pharmaceuticals Stock Is Plummeting Today","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxPWDBNcU9sQy1HRW5jMFFTbjE4WjU2NklsZnNaNmFOaHBkcEtCbTdSWXV1eEZ0ckNLQmloMmxqMHJDT0R6OVEzbUJmNkpqdHFmR0huSmhVdzRldnBTY2dMWlFTZUF2dWtCYl81TGdfYlk5SENBbUdxVXZ1YThqYnFtR1dpS2huazhDYkJZWEYyTWpYV3hCdGVkTlctOEoyMERXNzlVVVhrRng1TUdlRnhQbHlNQzJvMGlhMWc0U0U0bDBiZ1U?oc=5","date":"2025-12-29","type":"pipeline","source":"Reuters","summary":"Ultragenyx shares plunge as bone disease drug fails to reduce fracture rate - Reuters","headline":"Ultragenyx shares plunge as bone disease drug fails to reduce fracture rate","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3gFBVV95cUxQanVrRGFsY2dvVFlELURiLW5OLVBDQVhPbUhjNGVmanh0UnF6RWd2RU44ZHpPVGcxVkhmSG9BaW9GN3lfd0NCTzVYQmZ6MWlUckV4YURkMExzZW1DX183TjlLMUJpdXBESjJtdjh4ZXBJMnYyOTdYWTdBajhiLW9WczBUU2ZhV3VrSFBaUWpTZUpxa1VTeDlKY01sai1ZeFBleFdzTUlTVzRfUlctRGhuT09ERmZnaXMzNnJ2bHZaQ3RobkI0aTJHUUpFc2V2eFFKZmk1Q1RuMWh0YTdVd1E?oc=5","date":"2025-12-29","type":"trial","source":"Investing.com","summary":"Ultragenyx Pharma stock steady as Truist reiterates Buy rating despite trial setbacks - Investing.com","headline":"Ultragenyx Pharma stock steady as Truist reiterates Buy rating despite trial setbacks","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxQWVlrci1jQ2h4anhVT0Q5ZmJlMmxWVUxORXprZzRIVHJNb0xQcXdCT21xOXp5YXVGcVN3OF9JUnE2NE1fa2F0YnBxWkpnZXpreDFMTHE3Vmp1WHVxZk1sSU1HcmZVaXVZNkZHSlQ3LUVaTng2cVRHMUktbHV0NXh1TkZBZkhHWklXU2xaQzl1WU85VGktUlh3eUY3a1hVS2tFZkZuMzZjcDF2bXRKNnFTd2V5NjZTZkRRaS1tdFVGSXZ5V1ZaRlN3?oc=5","date":"2025-08-21","type":"pipeline","source":"Fierce Pharma","summary":"Rezolute resolves commercial question, hiring ex-Ultragenyx exec to ready for rare disease launch - Fierce Pharma","headline":"Rezolute resolves commercial question, hiring ex-Ultragenyx exec to ready for rare disease launch","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxQMm9UUGhDejFhb1E1ellab0VfR0ZJM0xqY29zZWw2S2JMMWtsMzFLN05LZEV2TFZlT3lUTTVFWF9renU5NkRKUlNLZmhBTzE3RUxRdG1kZGdwQmlJc3ptME4yYXREOFNqQmN5UmtzRjJRd2ZFQXFISVFOVjVYaTA3RDUyRVFXMDhadjBGdThLamhmSjliZDU3cDFR?oc=5","date":"2025-07-14","type":"pipeline","source":"Investor's Business Daily","summary":"Why This Beleaguered Biotech Just Took Another Hit - Investor's Business Daily","headline":"Why This Beleaguered Biotech Just Took Another Hit - Investor's Business Daily","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTE9DMDNsMzd5d3NXYVk2cWZnT0RTNV9nTHZpYjdOMnZsYjNrcy1Zc2p0Nm1VRC1RbVNSNzU4Z3U1NlRYazBEWmw1NnZ1OUVRUDVPT044WlkzMnYyNEJqcjEybllld2xKbmxHY0pWTzdwZWoxVmFWaFF3UXJtVQ?oc=5","date":"2025-07-10","type":"trial","source":"Barron's","summary":"Biotech Stock Ultragenyx Is Falling on Unsatisfying Trial Update - Barron's","headline":"Biotech Stock Ultragenyx Is Falling on Unsatisfying Trial Update - Barron's","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxQRF9VcGtnQXdmVG5oOXI5UXpCNWJwQ2RCT0hWLVZCakxxQ1FONnpudGcxa1FGV3U3YnJESzhVTW1tOUFibHAwdVdFbTFUdHZYck9qUmJ0ZnBybFFvcGFRZWxnMWJWTHlZMUR0Xy1neldiMXZ4bzB3RWdqUWhycWl2SmVLVFBJUDhvZl9aRXpDdnJzM25RYlhpZDk4U0poSVZOQ19qMlJnR24wc2tuMmVUV1p2UXlIY00?oc=5","date":"2025-07-10","type":"trial","source":"Seeking Alpha","summary":"Ultragenyx: 'Hold' The Best Strategy As Stock Tanks On Bone Disease Study Miss (RARE) - Seeking Alpha","headline":"Ultragenyx: 'Hold' The Best Strategy As Stock Tanks On Bone Disease Study Miss (RARE)","sentiment":"negative"}],"patents":[{"drugName":"Mepsevii","drugSlug":"velaglucerase-alfa","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":143800000}],"drugCount":7,"phaseCounts":{"phase_3":4,"phase_2":1,"marketed":1,"phase_1":1},"enrichmentLevel":3,"visitCount":3,"keyCompetitors":["BioMarin Pharmaceutical","Shire plc","Alexion Pharmaceuticals"],"therapeuticFocus":["Rare Diseases","Genetic Disorders"],"financials":{"source":"sec_edgar+yahoo","revenue":673000000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":673000000,"period":"2025-12-31"},{"value":560230000,"period":"2024-12-31"},{"value":560000000,"period":"2024-12-31"},{"value":434249000,"period":"2023-12-31"},{"value":434249000,"period":"2023-12-31"}],"grossProfit":564000000,"grossProfitHistory":[{"period":"2025-12-31","value":564000000},{"period":"2024-12-31","value":483000000},{"period":"2023-12-31","value":389000000},{"period":"2022-12-31","value":335009000}],"rdSpend":750000000,"rdSpendHistory":[{"period":"2025-12-31","value":750000000},{"period":"2024-12-31","value":698000000},{"period":"2023-12-31","value":648000000},{"period":"2022-12-31","value":705789000}],"sgaSpend":349000000,"operatingIncome":-535000000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-535000000},{"period":"2024-12-31","value":-536000000},{"period":"2023-12-31","value":-569000000},{"period":"2022-12-31","value":-648919000}],"netIncome":-575000000,"netIncomeHistory":[{"period":"2025-12-31","value":-575000000},{"period":"2024-12-31","value":-569000000},{"period":"2023-12-31","value":-607000000},{"period":"2022-12-31","value":-707421000}],"eps":-5.83,"epsHistory":[{"period":"2025-12-31","value":-5.83},{"period":"2024-12-31","value":-6.29},{"period":"2023-12-31","value":-8.25},{"period":"2022-12-31","value":-10.12}],"cash":421000000,"cashHistory":[{"period":"2025-12-31","value":421000000},{"period":"2024-12-31","value":174000000},{"period":"2023-12-31","value":213584000},{"period":"2022-12-31","value":132944000}],"totalAssets":1532000000,"totalLiabilities":1605000000,"totalDebt":36000000,"equity":-80000000,"operatingCashflow":-466000000,"operatingCashflowHistory":[{"period":"2025-12-31","value":-466000000},{"period":"2024-12-31","value":-414000000},{"period":"2023-12-31","value":-475000000},{"period":"2022-12-31","value":-380465000}],"capex":-21000000,"capexHistory":[{"period":"2025-12-31","value":-21000000},{"period":"2024-12-31","value":-20000000},{"period":"2023-12-31","value":-47000000},{"period":"2022-12-31","value":-146123000}],"freeCashflow":-487000000,"dividendsPaid":null,"buybacks":null,"employees":1371,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":88000000,"ebit":-163000000,"ebitda":-155000000,"period":"2026-03-31","revenue":136000000,"epsBasic":-1.84,"netIncome":-185000000,"rdExpense":187000000,"epsDiluted":-1.84,"grossProfit":106000000,"operatingIncome":-169000000},{"sga":87937000,"ebit":-108217000,"ebitda":-99432000,"period":"2025-12-31","revenue":207279000,"epsBasic":-1.29,"netIncome":-128556000,"rdExpense":203280000,"epsDiluted":-1.29,"grossProfit":177934000,"operatingIncome":-113283000},{"sga":86620000,"ebit":-165392000,"ebitda":-156786000,"period":"2025-09-30","revenue":159933000,"epsBasic":-1.81,"netIncome":-180413000,"rdExpense":216212000,"epsDiluted":-1.81,"grossProfit":131942000,"operatingIncome":-170890000},{"sga":86646000,"ebit":-99963000,"ebitda":-91354000,"period":"2025-06-30","revenue":166496000,"epsBasic":-1.17,"netIncome":-114951000,"rdExpense":164736000,"epsDiluted":-1.17,"grossProfit":143494000,"operatingIncome":-107888000},{"sga":87000000,"ebit":-136000000,"ebitda":-127000000,"period":"2025-03-31","revenue":139000000,"epsBasic":-1.57,"netIncome":-151000000,"rdExpense":166000000,"epsDiluted":-1.57,"grossProfit":110000000,"operatingIncome":-143000000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-12-31","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":25.98,"previousClose":26.46,"fiftyTwoWeekHigh":42.37,"fiftyTwoWeekLow":18.29,"fiftyTwoWeekRange":"18.29 - 42.37","fiftyDayAverage":23.05,"twoHundredDayAverage":27.68,"beta":0.39,"enterpriseValue":3392086784,"forwardPE":181.7,"priceToBook":-31.3,"priceToSales":3.82,"enterpriseToRevenue":5.06,"enterpriseToEbitda":-6.83,"pegRatio":0,"ebitda":-497000000,"ebitdaMargin":-74.2,"freeCashflow":-219090000,"operatingCashflow":-497000000,"totalDebt":1200000000,"debtToEquity":0,"currentRatio":2.02,"returnOnAssets":-25.5,"returnOnEquity":0,"analystRating":"1.5 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":20,"targetMeanPrice":52.75,"targetHighPrice":84,"targetLowPrice":25,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":3.4,"institutionHeldPercent":94.7,"sharesOutstanding":98489224,"floatShares":94628883,"sharesShort":13665812,"shortRatio":7.48,"shortPercentOfFloat":13.9,"epsTrailing":-6.1,"epsForward":0.14,"revenuePerShare":6.72,"bookValue":-0.83,"officers":[{"age":65,"name":"Dr. Emil D. Kakkis M.D., Ph.D.","title":"Founder, President, CEO & Director"},{"age":46,"name":"Mr. Howard  Horn","title":"Executive VP of Corporate Strategy & CFO"},{"age":47,"name":"Ms. Karah Herdman Parschauer J.D.","title":"Chief Legal Officer & Executive VP of Corporate Affairs"},{"age":55,"name":"Mr. Erik  Harris M.B.A.","title":"Executive VP & Chief Commercial Officer"},{"age":52,"name":"Dr. Eric  Crombez M.D.","title":"Chief Medical Officer & Executive VP"},{"age":54,"name":"Mr. Theodore A. Huizenga","title":"Senior VP, Corporate Controller & Principal Accounting Officer"},{"age":60,"name":"Mr. Ernie W. Meyer","title":"Chief Human Resources Officer & Executive VP"},{"age":60,"name":"Mr. Vimal  Srivastava","title":"Senior Vice President of Business Development & Alliance Management"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.ultragenyx.com","phone":"415 483 8800"}}